Skip to main content

TELA Bio, Inc. (TELA)

NASDAQ: TELA · IEX Real-Time Price · USD
12.65 0.16 (1.28%)
Dec 8, 2021 4:00 PM EST - Market closed
Market Cap183.47M
Revenue (ttm)26.76M
Net Income (ttm)-32.45M
Shares Out14.50M
EPS (ttm)-2.24
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,413
Open12.45
Previous Close12.49
Day's Range11.91 - 12.69
52-Week Range11.03 - 18.00
Beta1.66
AnalystsBuy
Price Target19.00 (+50.2%)
Earnings DateNov 10, 2021

About TELA

TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine...

IndustryHealth Care Equipment & Supplies
IPO DateNov 8, 2019
Employees108
Stock ExchangeNASDAQ
Ticker SymbolTELA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for TELA Bio stock is "Buy." The 12-month stock price forecast is 19.00, which is an increase of 50.20% from the latest price.

Price Target
$19.00
(50.20% upside)
Analyst Consensus: Buy

News

TELA Bio, Inc. (TELA) Reports Q3 Loss, Tops Revenue Estimates

TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -9.62% and 4.85%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

4 weeks ago - Zacks Investment Research

TELA Bio Reports Strong Third Quarter 2021 Revenues Reflecting Continued Growth Driven by Increased Demand

MALVERN, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue re...

4 weeks ago - GlobeNewsWire

TELA Bio Announces Publication of 12-Month Results from the BRAVO Study with Continued Positive Outcomes Through 24 m...

MALVERN, Pa., Nov. 09, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc . (NASDAQ: TELA), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcem...

4 weeks ago - GlobeNewsWire

TELA Bio to Participate in Three Upcoming Conferences

MALVERN, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement mat...

1 month ago - GlobeNewsWire

Will TELA Bio, Inc. (TELA) Report Negative Q3 Earnings? What You Should Know

TELA Bio, Inc. (TELA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

TELA Bio and Next Science Enter into Exclusive Distribution Agreement in the Plastic Reconstructive Market for Advanc...

Agreement includes exclusive right to sell and market Next Science's proprietary no rinse antimicrobial solution in the US and first right of negotiation for EU market upon CE Approval Agreement include...

1 month ago - GlobeNewsWire

TELA Bio to Announce Third Quarter 2021 Financial Results

MALVERN, Pa., Oct. 27, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement mat...

1 month ago - GlobeNewsWire

TELA Bio Appoints Roberto Cuca as Chief Operating Officer and Chief Financial Officer

MALVERN, Pa., Sept. 27, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement ma...

2 months ago - GlobeNewsWire

TELA Bio® Announces New Data on Use of OviTex in a Range of Hernia Repair Applications, Including Novel ReBAR (Reinfo...

Positive results presented at the 2021 Society of American Gastrointestinal and Endoscopic Surgeons Meeting show advancement in hernia repair options Positive results presented at the 2021 Society of Am...

2 months ago - GlobeNewsWire

TELA Bio's OviTex® Reinforced Tissue Matrix to be Featured in Three Presentations at SAGES 2021

Innovative medtech company celebrates upcoming poster presentations for its advanced hernia reinforcement material at industry-leading conference Innovative medtech company celebrates upcoming poster pr...

3 months ago - GlobeNewsWire

TELA Bio, Inc. (TELA) Reports Q2 Loss, Tops Revenue Estimates

TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -16.33% and 18.09%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

TELA Bio: Q2 Earnings Insights

Shares of TELA Bio (NASDAQ:TELA) decreased 2.3% after the company reported Q2 results. Quarterly Results Earnings per share decreased 7.55% over the past year to ($0.57), which missed the estimate of ($...

3 months ago - Benzinga

TELA Bio Reports Record Second Quarter 2021 Revenues Driven by Increased Demand

MALVERN, Pa., Aug. 11, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue re...

3 months ago - GlobeNewsWire

TELA Bio, Inc. (TELA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

TELA Bio, Inc. (TELA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

TELA Bio to Participate in Canaccord Genuity's 41st Annual Growth Conference

MALVERN, Pa., Aug. 03, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement mat...

4 months ago - GlobeNewsWire

NHS Surgeon First in Europe to Implant TELA Bio's OviTex® LPR Reinforced Tissue Matrix

Mr. Paul Wilson, Consultant General Surgeon, successfully completes complex hernia repair with minimally invasive approach Mr. Paul Wilson, Consultant General Surgeon, successfully completes complex her...

4 months ago - GlobeNewsWire

New Strong Sell Stocks for June 18th

OEG, EAF, RARE, EGRX, and TELA have been added to the Zacks Rank #5 (Strong Sell) List on June 18, 2021

Other symbols:EAFEGRXOEGRARE
5 months ago - Zacks Investment Research

TELA Bio to Participate in Upcoming JMP Securities Life Sciences Conference

MALVERN, Pa., June 14, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement mat...

5 months ago - GlobeNewsWire

TELA Bio to Participate in Upcoming Investor Conferences

MALVERN, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement mate...

6 months ago - GlobeNewsWire

TELA Bio Launches Post Market Study Of OviTex In Hernia Surgery

TELA Bio Inc (NASDAQ: TELA) has launched its second post-market study, BRAVO II, to evaluate the clinical performance of OviTex Reinforced Tissue Matrices in the robotic repair of ventral hernias. The s...

6 months ago - Benzinga

TELA Bio Initiates BRAVO II Study of OviTex® for the Robotic Repair of Ventral Hernias

MALVERN, Pa., May 19, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement mate...

6 months ago - GlobeNewsWire

TELA Bio, Inc. (TELA) Reports Q1 Loss, Tops Revenue Estimates

TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -27.27% and 4.02%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

TELA Bio: Q1 Earnings Insights

Shares of TELA Bio (NASDAQ:TELA) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 11.11% year over year to ($0.56), which missed the estim...

6 months ago - Benzinga

TELA Bio Announces First Quarter 2021 Financial Results

MALVERN, Pa., May 13, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing, and marketing innovative tissue rei...

6 months ago - GlobeNewsWire

TELA Bio to Announce First Quarter 2021 Financial Results

MALVERN, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement ma...

7 months ago - GlobeNewsWire